Sepsis Therapeutics - Global Strategic Business Report

Description: This report analyzes the worldwide markets for Sepsis Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, and Rest of World.

Annual estimates and forecasts are provided for the period 2017 through 2022. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs. The report profiles 37 companies including many key and niche players such as -

Adrenomed AG
AM-Pharma B.V
Aridis Pharmaceuticals, Inc.
Asahi Kasei Pharma America
Astellas Pharma Inc.

Contents:

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW
Sepsis
A Prelude
Lack of Dedicated Sepsis Therapeutics
List of Sepsis Drug Candidates Discontinued from Development or Withdrawn from the Market (As of 2016)
Competition and Pipeline
Current Categories of Antibacterial Agents for First-line Sepsis Treatment
Select Sepsis Therapeutics under Pipeline: 2016
Current & Future Analysis
Growth Drivers in a Nutshell:
Market Restraints:
Overhaul of Clinical Trial Strategy Needed
Novel Immune-Specific Modes of Action Under Focus
Drug Resistance: The Major Threat to Sepsis Standby Antibiotics
Aging Population Statistics: Key Opportunity Indicator for Sepsis Therapeutics
Table 1: Elderly Population (60+ Years) as a Percentage of Total Population (2015 & 2050) (includes corresponding Graph/Chart)
Table 2: Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in ‘000s and as a Percentage of Total Population for 2015 & 2050 (includes corresponding Graph/Chart)

2. SEPSIS THERAPEUTICS INNOVATIONS
MDx for Sepsis
Practical Challenges Galore
T2Dx System: Enabling Rapid Diagnosis of Sepsis
CytoSorb®: Addressing Sepsis by Removal of Cytokines

3. SEPSIS: AN OVERVIEW
Sepsis
A Leading Killer
Risk Profile
Most Vulnerable Groups: Newborns and the Elderly
A Growing Threat in Hospital Environment
Types of Sepsis
SIRS
Uncomplicated Sepsis
Severe Sepsis
Septic Shock
Septicemia
Bacteremia
Mortality Rates
Symptoms to Identify Sepsis Patients
General Symptoms in Sepsis Patients
Symptoms Specific to Source of Infection
Biological Changes in Sepsis Patients
Organ Dysfunction Symptoms in Acute Cases
Common Sources of Sepsis
Stages of Sepsis' Progression
Treatment of Sepsis
General Approaches for Treatment of Severe Sepsis and Septic Shock
First Line of Treatment
Identifying Infection Source
Overview of Traditional Treatment Approaches
Corticosteroids
Immunoglobulins
Anticoagulants
Neonatal Sepsis

4. CLINICAL TRIALS
SciClone Pharmaceuticals Starts Phase 3 Trial of ZADAXIN for Sepsis
InflaRx Announces Positive Phase IIa Results of mAb IFX-1 for Septic Organ Dysfunction
TiGenix NV Receives €5.4M Grant from EC for Phase Ib/Ila Trial of SEPCELL
T2 Biosystems Announces Positive Results from Investigational Study on its T2Candida Panel
TiGenix NV Completes Phase I Trial of Cx611 in Sepsis Challenge Model

5. PRODUCT INTRODUCTIONS/APPROVALS
Thermo Fisher Scientific Receives FDA Clearance for B·R·A·H·M·S PCT
Response Biomedical's RAMP® Test Receives Health Canada Approval and CE Mark
Wyss Institute of Harvard University Improves its Sepsis Therapeutic Device
Immunexpress to Present Data on its SeptiCyte® Lab test for Sepsis Assessment
Deutsche Biotech Strengthens IP on its Sepsis Drug Candidate Adrecizumab
DSX Therapeutics and R&D Ab® Receive EU Patents for mAb-based Sepsis Therapy
Bruker Introduces IVD MALDI Sepsityper™ Kit for Rapid Identification of Sepsis Microbes
SRL Diagnostics Launches 'Sepsiscreen' Test to Diagnose Sepsis
Abbott's Infectious Pathogen-testing Platform IRIDICA Available in Europe
Arch Biopartners Introduces Sepsis Drug Candidate Metablok to its Pipeline

6. RECENT INDUSTRY ACTIVITY
Sepset Biosciences Spins off from CDRD
Cyon Therapeutics Acquires Rights on LGT-209 for Sepsis Treatment from Novartis
Luminex Corporation Acquires Nanosphere
bioMérieux to Collaborate with Sepsis Alliance
TiGenix Selects TFS International for its First Trial SEPCELL
Wyss Institute Launches its Startup Company Opsonix to Commercialize Sepsis Therapy
Curetis Enters into Distribution Agreement with Acumen
Tenax Therapeutics Partners with Sepsis Alliance
Biocartis and Microbiome Enter into Collaboration Agreement for Rapid Sepsis Assay
Vivione Biosciences to Acquire Sepsis Player Trillium Diagnostics
Inotrem Completes Series A Financing
TheraNova Spins out Sepsis Company Consano Medical

7. FOCUS ON SELECT GLOBAL PLAYERS
Adrenomed AG (Germany)
AM-Pharma B.V. (Netherlands)
Aridis Pharmaceuticals, Inc. (US)
Asahi Kasei Pharma America (US)
Astellas Pharma Inc. (Japan)
Bristol-Myers Squibb Company (US)
Chong Kun Dang BiO Corp. (South Korea)
Endacea, Inc. (US)
InflaRx GmbH (Germany)
Opsona Therapeutics Ltd. (Ireland)
Opsonix, Inc. (US)
T2 Biosystems, Inc. (US)
TaiRx, Inc. (US)
TiGenix NV (Belgium)

8. GLOBAL MARKET PERSPECTIVE
Table 3: World Recent Past, Current & Future Analysis for Sepsis Therapeutics by Geographic Region/Country
US, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2017 through 2022 (includes corresponding Graph/Chart)
Table 4: World 6-Year Perspective for Sepsis Therapeutics by Geographic Region/Country
Percentage Breakdown of Dollar Sales for US, and Rest of World Markets for Years 2017 and 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES
A. Market Analysis
Alarming Incidence of Sepsis & Lack of Therapies
Table 5: Estimated Annual Incidence of Septic Shock in the US (2016-2022E) (includes corresponding Graph/Chart)
Select Sepsis Therapeutics in the Pipeline: 2016
United States: The Largest Market for Sepsis Therapeutics
Innovative AMC Device to Filter Blood and Address Sepsis
Aging Population: A Key Growth Factor
Table 6: Aging Population in the US (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
Clinical Trials
Product Launches/Approvals
Strategic Corporate Developments
Select Key Players
B. Market Analytics
Table 8: The US Recent Past, Current & Future Analysis for Sepsis Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2017 through 2022 (includes corresponding Graph/Chart)

2. REST OF WORLD
A. Market Analysis
Canada
Canadian Researchers Working on Cholesterol Drug for Sepsis Treatment
Aging Population: Key Opportunity Indicator
Table 9: Aging Population in Canada (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
Europe
European Players Focus on Biomarkers and Multi Marker Panels for Timely Sepsis Management
Increasing Incidence of Aging Population: Key Opportunity Indicator for Sepsis Therapeutics
Table 10: Aging Population in Europe by Country (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
United Kingdom
NHS under Fire after Child Sepsis Deaths
Favorable Government Policies
A Ray of Sunshine
“RAPPID” Technology Fuels Growth for Ongoing R&D Initiatives
India
India: High Incidence of Neonatal Sepsis
Table 11: Estimated Incidence and Mortality Associated with AIDS, Breast Cancer, MI, and Sepsis in India (includes corresponding Graph/Chart)

Key Opportunity Indicator: Aging Population Statistics in Rest of World

Table 12: Aging Population in Asia-Pacific by Country (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)

Table 13: Aging Population in Latin America by Country (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)

Table 14: Aging Population in the Middle East by Country (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)

Table 15: Aging Population in Africa by Region (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)

Clinical Trials

Product Launches/Approvals

Strategic Corporate Developments

Select Key Players

B. Market Analytics

Table 16: Rest of World Recent Past, Current & Future Analysis for Sepsis Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2017 through 2022 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 37

The United States (12)

Canada (4)

Japan (4)

Europe (11)

- France (1)
- Germany (4)
- The United Kingdom (1)
- Rest of Europe (5)

Asia-Pacific (Excluding Japan) (6)

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/1882061/](http://www.researchandmarkets.com/reports/1882061/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,

Guinness Centre,

Taylors Lane,

Dublin 8,

Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Sepsis Therapeutics - Global Strategic Business Report
Web Address: http://www.researchandmarkets.com/reports/1882061/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
<td>USD 4500</td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 - 5 Users:</td>
<td></td>
<td>USD 6300</td>
</tr>
<tr>
<td>1 - 10 Users:</td>
<td></td>
<td>USD 8550</td>
</tr>
<tr>
<td>1 - 15 Users:</td>
<td></td>
<td>USD 10800</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Field</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title:</td>
<td>Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐</td>
</tr>
<tr>
<td>First Name:</td>
<td>_________________________</td>
</tr>
<tr>
<td>Last Name:</td>
<td>_________________________</td>
</tr>
<tr>
<td>Email Address: *</td>
<td>_________________________</td>
</tr>
<tr>
<td>Job Title:</td>
<td>_________________________</td>
</tr>
<tr>
<td>Organisation:</td>
<td>_________________________</td>
</tr>
<tr>
<td>Address:</td>
<td>_________________________</td>
</tr>
<tr>
<td>City:</td>
<td>_________________________</td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td>_________________________</td>
</tr>
<tr>
<td>Country:</td>
<td>_________________________</td>
</tr>
<tr>
<td>Phone Number:</td>
<td>_________________________</td>
</tr>
<tr>
<td>Fax Number:</td>
<td>_________________________</td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by Wire Transfer: Bank details will be provided on the invoice which you will receive after you place your order with us.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World